<DOC>
	<DOCNO>NCT02523794</DOCNO>
	<brief_summary>The purpose study evaluate efficacy electro-kinetically modified water ( EMW ) beverage , consume twice daily ( BID ) 3 month management endometriosis associate pain , evaluate effect EMW consumption analgesic use endometriosis associate pain .</brief_summary>
	<brief_title>Study Electro-kinetically Modified Water Treatment Pain Associated With Endometriosis</brief_title>
	<detailed_description>This single center , double-blind , placebo control , randomize study ass efficacy EMW versus placebo treatment premenopausal woman ( 16-49 year age ) endometriosis associate pain . Approximately 40 subject endometriosis enrol Madigan Army Medical Center ( MAMC ) . Subjects ask consume EMW ( placebo ) three month . Subjects record daily pain level symptom associate endometriosis electronic diary . In addition standard care condition , investigator monitor subject baseline , Month 1 , Month 3 visit , consist patient questionnaire , blood sampling , Adverse Events monitoring .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<criteria>Premenopausal woman , 16 49 year age Diagnosed endometriosis mean document surgical visualization ( laparoscopy laparotomy ) within 10 year study entry No endometriosisrelated surgical procedure within month start study agent Has least 2 day moderate severe pain score dysmenorrhea ( Ediary NRS &gt; 5 10 ) nonmenstrual pelvic pain ( Ediary NRS &gt; 5 10 ) month prior start study agent Must menstrual cycle interval 2435 day within 3 month start study agent BMI 18 39 Able provide write informed consent able comply study procedure entire length study Pregnant breastfeed plan pregnancy next 12 month Has pregnant within 3 month start study agent Has hysterectomy bilateral oophorectomy Has chronic pelvic pain cause endometriosis ( i.e . inflammatory bowl disease , irritable bowel syndrome , adenomyosis , interstitial cystitis , pelvic adhesive disease , pelvic inflammatory disease ) require chronic analgesic narcotic use would interfere assessment endometriosis associate pain Current history undiagnosed abnormal uterine bleed Currently receive Gonadotropinreleasing hormone ( GnRH ) agonist GnRH antagonist receive type medication within 6 month start study agent Currently receive subcutaneous medroxyprogesterone acetate ( DMPASC ) i.m . medroxyprogesterone acetate ( DMPAIM ) receive within last 3 month enrollment Currently intrauterine device place Use steroid immunosuppressive medication regular basis within 3 month enrollment Has unstable medical condition , chronic disease psychiatric disorder deem investigator incompatible participation study Treatment investigational drug/interventions within 3 month start study agent History drug alcohol abuse</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>